Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NASDAQ:BBIO NASDAQ:NAMS NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$241.97-2.4%$221.79$96.09▼$260.19$12.75B0.61657,982 shs1.31 million shsBBIOBridgeBio Pharma$68.63-0.4%$69.37$41.80▼$84.94$13.50B0.972.72 million shs2.45 million shsNAMSNewAmsterdam Pharma$31.40+1.9%$32.94$17.67▼$42.21$3.60B0.071.23 million shs999,802 shsRDYDr. Reddy's Laboratories$14.28+2.7%$13.38$12.19▼$15.71$11.61B0.271.56 million shs4.15 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-2.37%-3.95%+2.54%+49.57%+138.04%BBIOBridgeBio Pharma-0.42%+2.99%-0.71%-4.16%+62.75%NAMSNewAmsterdam Pharma+1.88%+4.01%-11.40%+1.26%+72.43%RDYDr. Reddy's Laboratories+2.63%+7.33%+5.03%+2.92%-6.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$241.97-2.4%$221.79$96.09▼$260.19$12.75B0.61657,982 shs1.31 million shsBBIOBridgeBio Pharma$68.63-0.4%$69.37$41.80▼$84.94$13.50B0.972.72 million shs2.45 million shsNAMSNewAmsterdam Pharma$31.40+1.9%$32.94$17.67▼$42.21$3.60B0.071.23 million shs999,802 shsRDYDr. Reddy's Laboratories$14.28+2.7%$13.38$12.19▼$15.71$11.61B0.271.56 million shs4.15 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-2.37%-3.95%+2.54%+49.57%+138.04%BBIOBridgeBio Pharma-0.42%+2.99%-0.71%-4.16%+62.75%NAMSNewAmsterdam Pharma+1.88%+4.01%-11.40%+1.26%+72.43%RDYDr. Reddy's Laboratories+2.63%+7.33%+5.03%+2.92%-6.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 2.95Moderate Buy$258.957.02% UpsideBBIOBridgeBio Pharma 2.84Moderate Buy$91.0532.66% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.6054.78% UpsideRDYDr. Reddy's Laboratories 1.67ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest NAMS, BBIO, AXSM, and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026AXSMAxsome Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$275.00 ➝ $300.006/16/2026BBIOBridgeBio Pharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$106.00 ➝ $96.006/15/2026AXSMAxsome Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/11/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)6/11/2026AXSMAxsome Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$380.006/11/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Overweight6/4/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026BBIOBridgeBio Pharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$104.005/29/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/28/2026BBIOBridgeBio Pharma Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$94.00 ➝ $98.005/28/2026BBIOBridgeBio Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$110.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$638.50M19.50N/AN/A$1.75 per share138.27BBIOBridgeBio Pharma$502.08M26.77N/AN/A($10.77) per share-6.37NAMSNewAmsterdam Pharma$22.50M163.14N/AN/A$5.97 per share5.26RDYDr. Reddy's Laboratories$3.58B3.33$0.87 per share16.42$4.86 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$183.17M-$3.73N/A51.81N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BBIOBridgeBio Pharma-$724.93M-$3.74N/A527.92N/A-124.42%N/A-65.81%8/4/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)RDYDr. Reddy's Laboratories$456M$0.5824.6221.971.9112.90%12.34%8.24%7/22/2026 (Estimated)Latest NAMS, BBIO, AXSM, and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2026Q1 26/27RDYDr. Reddy's Laboratories$0.1003N/AN/AN/A$830.50 millionN/A5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million5/7/2026Q1 2026BBIOBridgeBio Pharma-$0.70-$0.84-$0.14-$0.84$178.07 million$194.52 million5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABBIOBridgeBio PharmaN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.49%+6.96%12.07%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics2.271.391.32BBIOBridgeBio PharmaN/A1.521.48NAMSNewAmsterdam PharmaN/A9.769.76RDYDr. Reddy's Laboratories0.031.801.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BBIOBridgeBio Pharma99.85%NAMSNewAmsterdam Pharma89.89%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics20.60%BBIOBridgeBio Pharma14.23%NAMSNewAmsterdam Pharma12.74%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBBIOBridgeBio Pharma400195.86 million167.99 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableRDYDr. Reddy's Laboratories27,527834.65 million817.96 millionOptionableNAMS, BBIO, AXSM, and RDY HeadlinesRecent News About These CompaniesDr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United StatesJune 13, 2026 | businesswire.comNYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoYMay 29, 2026 | prnewswire.comDr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada NodMay 17, 2026 | theglobeandmail.comDr. Reddy's launches generic semaglutide in Canada, expands GLP-1 pushMay 16, 2026 | msn.comDr. Reddy's Laboratories Launches its Generic Semaglutide Injection in CanadaMay 16, 2026 | businesswire.comDr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock DownMay 13, 2026 | zacks.comDr. Reddy’s Laboratories Limited (NYSE:RDY) Q4 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comDr. Reddy's Laboratories Ltd (RDY) Releases Q4 2026 Earnings: Revenue and Profits Plunge, Margins CompressedMay 12, 2026 | quiverquant.comQDoctor Reddy’s: Fiscal Q4 Earnings SnapshotMay 12, 2026 | wtop.comWDr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comIndian drugmaker Dr Reddy's posts quarterly profit slumpMay 12, 2026 | reuters.comAMPH vs. RDY: Which Stock Should Value Investors Buy Now?April 29, 2026 | zacks.comCanada Approves Dr. Reddy's Generic Version of Novo Nordisk's OzempicApril 29, 2026 | wsj.comDr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in CanadaApril 29, 2026 | businesswire.comDr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 DiabetesMarch 23, 2026 | equitybulls.comEZacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy'sMarch 5, 2026 | finance.yahoo.com3 Generic Drug Stocks to Watch Despite Industry HeadwindsMarch 4, 2026 | zacks.comDr. Reddy’s biosimilar for Bristol’s Orencia undergoes FDA reviewFebruary 20, 2026 | seekingalpha.comDr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, AbataceptFebruary 20, 2026 | businesswire.comDr. Reddy’s Schedules Mumbai Investor Meet for February 23, 2026February 14, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, BBIO, AXSM, and RDY Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$241.97 -5.88 (-2.37%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$245.22 +3.25 (+1.34%) As of 06/23/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.BridgeBio Pharma NASDAQ:BBIO$68.63 -0.29 (-0.42%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$68.99 +0.36 (+0.53%) As of 06/23/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.NewAmsterdam Pharma NASDAQ:NAMS$31.40 +0.58 (+1.88%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$31.40 +0.01 (+0.02%) As of 06/23/2026 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$14.28 +0.37 (+2.66%) Closing price 06/23/2026 03:58 PM EasternExtended Trading$14.32 +0.04 (+0.28%) As of 06/23/2026 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
